ラニビズマブ単独治療の導入期に連続3回投与は必要か

Is it necessary to perform three sessions during induction of ranibizumab monotherapy?

要約　目的：滲出型加齢黄斑変性に対するラニビズマブ導入期連続3回投与の必要性についての検討。対象と方法：導入期途中でdry macula（網膜浮腫および網膜下液の両者を認めない状態）を得たため1回または連続2回で終了した31眼（2回以下群）と，導入期途中でdry maculaを得たが連続3回投与した14眼（3回群）の治療成績を後ろ向きに比較した。結果：中心窩網膜厚と視力の改善量は，1か月，2か月，3か月，6か月，12か月時において2群間で有意差がなかった。12か月間の投与回数は，2回以下群のほうが有意に少なかった。結論：導入期途中でdry maculaが得られれば，連続3回投与する必要性はない可能性がある。

Abstract.　Purpose：To discuss the necessity to repeat 3 sessions of intravitreal ranibizumab for exudative age-related macular degeneration（AMD）. Cases and Method：This study was made on 45 eyes of exudative AMD treated by intravitreal injection of ranibizumab. Treatment was discontinued after one or 2 sessions in 31 eyes after dry-macula state was achieved. It was performed in 3 sessions in the other 14 eyes. Results：There was no difference between the two groups regarding foveal thickness and imrovement of visual acuity after 1, 2, 3, 6, or 12 months. Number of sessions during 12 months was significantly less in eyes receiving one or 2 treatments only. Conclusion：Three consecutive sessions of intravitreal ranibizumab may not be necessary for exudative AMD after dry-macula state is achieved.